Whitehead Anne, Beck Eleanor J, Tosh Susan, Wolever Thomas M S
From the Medical & Pharmaceutical Statistics Research Unit, Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom (AW); the School of Medicine and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia (EJB); Agriculture and Agri-Food Canada, Guelph, Canada (ST); and the Department of Nutritional Sciences, University of Toronto, Toronto, Canada (TMSW).
Am J Clin Nutr. 2014 Dec;100(6):1413-21. doi: 10.3945/ajcn.114.086108. Epub 2014 Oct 15.
Health claims regarding the cholesterol-lowering effect of soluble fiber from oat products, approved by food standards agencies worldwide, are based on a diet containing ≥3 g/d of oat β-glucan (OBG). Given the number of recently published randomized controlled trials (RCTs), it is important to update the findings of previous meta-analyses.
The objective was to quantify the effect of ≥3 g OBG/d on serum cholesterol concentrations in humans and investigate potential effect modifiers.
A meta-analysis was performed on 28 RCTs comparing ≥3 g OBG/d with an appropriate control. Systematic searches were undertaken in PubMed, AGRICOLA, and Scopus between 1 January 1966 and 6 June 2013, plus in-house study reports at CreaNutrition AG. Studies were assessed with regard to inclusion/exclusion criteria, and data were extracted from included studies by reviewers working independently in pairs, reconciling differences by consensus. Estimates of the mean reduction in serum cholesterol from baseline between the OBG and control diets were analyzed by using random-effects meta-analysis models and meta-regression.
OBG in doses of ≥3 g/d reduced low-density lipoprotein (LDL) and total cholesterol relative to control by 0.25 mmol/L (95% CI: 0.20, 0.30; P < 0.0001) and 0.30 mmol/L (95% CI: 0.24, 0.35; P < 0.0001), respectively, with some indication of heterogeneity (P = 0.13 and P = 0.067). There was no significant effect of OBG on high-density lipoprotein (HDL) cholesterol or triglycerides and no evidence that dose (range across trials: 3.0-12.4 g/d) or duration of treatment (range: 2-12 wk) influenced the results. LDL cholesterol lowering was significantly greater with higher baseline LDL cholesterol. There was a significantly greater effect for both LDL and total cholesterol in subjects with diabetes compared with those without (although based on few studies).
Adding ≥3 g OBG/d to the diet reduces LDL and total cholesterol by 0.25 mmol/L and 0.30 mmol/L, respectively, without changing HDL cholesterol or triglycerides.
全球食品标准机构批准的关于燕麦产品中可溶性纤维降胆固醇作用的健康声明,是基于一种每日摄入≥3克燕麦β-葡聚糖(OBG)的饮食。鉴于近期发表的随机对照试验(RCT)数量众多,更新之前荟萃分析的结果很重要。
目的是量化每日摄入≥3克OBG对人体血清胆固醇浓度的影响,并研究潜在的效应修饰因素。
对28项将每日摄入≥3克OBG与适当对照进行比较的RCT进行荟萃分析。在1966年1月1日至2013年6月6日期间,在PubMed、AGRICOLA和Scopus数据库以及CreaNutrition AG的内部研究报告中进行了系统检索。根据纳入/排除标准对研究进行评估,数据由成对独立工作的评审人员从纳入研究中提取,通过协商一致解决差异。使用随机效应荟萃分析模型和荟萃回归分析OBG饮食与对照饮食之间血清胆固醇从基线水平降低的平均估计值。
每日摄入≥3克的OBG相对于对照,可使低密度脂蛋白(LDL)和总胆固醇分别降低0.25 mmol/L(95%CI:0.20,0.30;P<0.0001)和0.30 mmol/L(95%CI:0.24,0.35;P<0.0001),有一些异质性迹象(P = 0.13和P = 0.067)。OBG对高密度脂蛋白(HDL)胆固醇或甘油三酯没有显著影响,也没有证据表明剂量(各试验范围:3.0 - 12.4克/天)或治疗持续时间(范围:2 - 12周)会影响结果。基线LDL胆固醇水平越高,LDL胆固醇降低越显著。与非糖尿病患者相比,糖尿病患者的LDL和总胆固醇降低效果更显著(尽管基于少数研究)。
在饮食中添加每日≥3克OBG可使LDL和总胆固醇分别降低0.25 mmol/L和0.30 mmol/L,而不改变HDL胆固醇或甘油三酯。